ATE400570T1 - 2,4,6-trisubstituierte pyrimidine als inhibitoren von phosphatidylinosit-(pi-)3-kinase und deren verwendung bei der behandlung von krebs - Google Patents

2,4,6-trisubstituierte pyrimidine als inhibitoren von phosphatidylinosit-(pi-)3-kinase und deren verwendung bei der behandlung von krebs

Info

Publication number
ATE400570T1
ATE400570T1 AT05758844T AT05758844T ATE400570T1 AT E400570 T1 ATE400570 T1 AT E400570T1 AT 05758844 T AT05758844 T AT 05758844T AT 05758844 T AT05758844 T AT 05758844T AT E400570 T1 ATE400570 T1 AT E400570T1
Authority
AT
Austria
Prior art keywords
sup
trisubsutituted
phosphatidylinosite
pyrimidines
kinase
Prior art date
Application number
AT05758844T
Other languages
English (en)
Inventor
John Bailey
Michael Giles
Martin Pass
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE400570T1 publication Critical patent/ATE400570T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT05758844T 2004-07-09 2005-07-07 2,4,6-trisubstituierte pyrimidine als inhibitoren von phosphatidylinosit-(pi-)3-kinase und deren verwendung bei der behandlung von krebs ATE400570T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0415365.6A GB0415365D0 (en) 2004-07-09 2004-07-09 Pyrimidine derivatives

Publications (1)

Publication Number Publication Date
ATE400570T1 true ATE400570T1 (de) 2008-07-15

Family

ID=32865683

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05758844T ATE400570T1 (de) 2004-07-09 2005-07-07 2,4,6-trisubstituierte pyrimidine als inhibitoren von phosphatidylinosit-(pi-)3-kinase und deren verwendung bei der behandlung von krebs

Country Status (15)

Country Link
US (1) US20080058332A1 (de)
EP (1) EP1768978B1 (de)
JP (1) JP2008505875A (de)
CN (1) CN101014590A (de)
AT (1) ATE400570T1 (de)
AU (1) AU2005261551A1 (de)
BR (1) BRPI0513058A (de)
CA (1) CA2571748A1 (de)
DE (1) DE602005008065D1 (de)
GB (1) GB0415365D0 (de)
IL (1) IL180136A0 (de)
MX (1) MX2007000119A (de)
NO (1) NO20070655L (de)
WO (1) WO2006005914A1 (de)
ZA (1) ZA200700054B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2316831T3 (da) 2002-11-21 2013-06-10 Novartis Ag 2-(Morpholin-4-yl)pyrimidiner som phosphotidylinositol (PI)-3-kinaseinhibitorer samt deres anvendelse ved behandling af cancer
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
GB0525081D0 (en) * 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
GB0525080D0 (en) * 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
GB0525083D0 (en) * 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
US8999984B2 (en) 2006-05-26 2015-04-07 University Of Louisville Research Foundation, Inc. Macrophage migration inhibitory factor antagonists and methods of using same
WO2008023159A1 (en) * 2006-08-24 2008-02-28 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
WO2008032041A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab Pyrimidine derivatives having inhibitory activity against pi3k enzymes
CA2675558A1 (en) 2007-02-06 2008-08-14 Novartis Ag Pi 3-kinase inhibitors and methods of their use
JP2010533159A (ja) * 2007-07-09 2010-10-21 アストラゼネカ アクチボラグ 化合物947
WO2009007750A1 (en) * 2007-07-09 2009-01-15 Astrazeneca Ab Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k
WO2010120994A2 (en) * 2009-04-17 2010-10-21 Wyeth Llc Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
PE20120640A1 (es) 2009-07-02 2012-06-09 Sanofi Sa Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt (pkb)
WO2011038234A2 (en) 2009-09-24 2011-03-31 University Of Louisville Research Foundation, Inc. Novel iodo pyrimidine derivatives useful for the treatment of macrophage migration inhibitory factor (mif)-implicated diseases and conditions
US8669380B2 (en) 2009-11-02 2014-03-11 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
WO2011146824A1 (en) 2010-05-20 2011-11-24 University Of Louisville Research Foundation, Inc. Methods and compositions for modulating ocular damage
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
MX342326B (es) 2011-09-27 2016-09-26 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
CA2903979A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
CN104151256B (zh) * 2014-08-14 2016-08-24 西安交通大学 二取代苯甲酰胺类化合物及其合成方法和应用
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
CN107793365B (zh) * 2016-08-31 2021-08-17 上海微创医疗器械(集团)有限公司 一种化合物及其制备方法和用途
CN109715163B (zh) 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
WO2018203219A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
EP4563150A3 (de) 2019-05-13 2025-07-23 Novartis AG Neue kristalline formen von n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonikotinamid als raf-hemmer zur behandlung von krebs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19836697A1 (de) * 1998-08-13 2000-02-17 Hoechst Marion Roussel De Gmbh Substituierte 4-Amino-2-aryl-pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
AU5261001A (en) * 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives

Also Published As

Publication number Publication date
MX2007000119A (es) 2007-03-09
CA2571748A1 (en) 2006-01-19
US20080058332A1 (en) 2008-03-06
IL180136A0 (en) 2007-06-03
JP2008505875A (ja) 2008-02-28
ZA200700054B (en) 2008-05-28
AU2005261551A1 (en) 2006-01-19
EP1768978A1 (de) 2007-04-04
BRPI0513058A (pt) 2008-04-22
NO20070655L (no) 2007-03-21
CN101014590A (zh) 2007-08-08
WO2006005914A1 (en) 2006-01-19
EP1768978B1 (de) 2008-07-09
DE602005008065D1 (de) 2008-08-21
GB0415365D0 (en) 2004-08-11

Similar Documents

Publication Publication Date Title
DE602005008065D1 (de) Von phosphatidylinosit-(pi-)3-kinase und deren verwendung bei der behandlung von krebs
DE602004011199D1 (de) 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren
NO20070656L (no) 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft
ATE353888T1 (de) Chinazolinderivate
GEP20105074B (en) Pyrimidinyl aryl urea derivatives being fgf inhibitors
TW200616978A (en) Quinazolinone derivatives as parp inhibitors
MY169515A (en) Quinazolinedione derivatives as parp inhibitors
ATE433447T1 (de) Pyrimiidinverbindungen
TW200519106A (en) Organic compounds
DE60215178D1 (de) Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase
NO20064062L (no) Prodroger av piperazin og substituerte piperidin antivirale midler
NO20070681L (no) 2, 4, 6-Trisubstituterte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse i behandling av kreft
UA91002C2 (ru) 7-фенилалкилзамещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поле(адф-рибоза)полимеразы
SE0300480D0 (sv) Novel compounds
ATE524181T1 (de) Verwendung von 1,4-bis (3-aminoalkyl) piperazin- derivaten bei der behandlung von neurodegenerativen erkrankungen
ATE553095T1 (de) Neue imidazolderivate, deren herstellung und deren verwendung als intermediate zur herstellung von arzneimitteln und pestiziden
ATE413392T1 (de) Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren
DE602006020295D1 (de) Azabenzimidalzolderivate, ihre herstellung und ihre verwendung als antikrebsmittel
ATE543803T1 (de) 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren
ATE482955T1 (de) Azabicyclooctan-3-onderivate und deren verwendung
ATE429230T1 (de) Chinazoline derivative und ihre anwendung in der krebsbehandlung
ATE530552T1 (de) Pyrrolobenzimidazolone und deren verwendung als antiproliferative mittel
DE602004007284D1 (de) Pyrimidine als inhibitoren von phosphoinositid-3-kinasen (pi3k)
WO2007068473A3 (en) Organic compounds
DE50010403D1 (de) Polycyclische thiazol-systeme und ihre verwendung als anorektika

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties